Clinical Trials
19 trialsKISS
University of Auckland, New Zealand
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Shenzhen Second People's Hospital
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Nanfang Hospital, Southern Medical University
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
LanZhou University
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
First Affiliated Hospital Xi'an Jiaotong University
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
First Affiliated Hospital Xi'an Jiaotong University
READIT
National Research Center for Hematology, Russia
TRAD
University Health Network, Toronto
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
DASAPOST
PETHEMA Foundation
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
Kanto CML Study Group
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Shimousa Hematology Study Group
D'ACCORD
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
National Cancer Institute (NCI)